GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2009

ChemDiv Purchases Prudentas to Strengthen Foothold in Eastern Europe

  • ChemDiv is expanding its CRO activities through the acquisition of Prudentas. ChemDiv believes that Prudentas’ range of services covering Phase I through Phase IV studies in Eastern Europe will add to its Discovery outSource™.

    “Our decision to make this investment capitalizes on the growing trend of conducting clinical trials in Eastern Europe based on the availability of naive patient populations, rapid and efficient trial recruitment, and high data quality across a broad range of therapeutic indications including CNS, cardiovascular and metabolic disorders, oncology, inflammation, and infectious disease; areas already covered by our Discovery outSource service,” explains Nikolay Savchuk, president and CEO of ChemDiv.

    ChemDiv previously worked with Prudentas in response to a growing partner base interested in conducting clinical trials. Now ChemDiv’s ChemRar High Tech Center will take over Prudentas. It will operate separately under the business name Prudentas LLC, a ChemDiv Group company.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »